反応式
NC[C@@H]1[C@H](C)CCCN1C(C1C=C(C)C=CC=1C1C=NN(C)C=1)=O.[C:25]1([C:35]([N:37]2[CH2:42][CH2:41][CH2:40][C@@H:39]([CH3:43])[C@H:38]2[CH2:44][N:45]2C(=O)C3C(=CC=CC=3)C2=O)=[O:36])[C:34]2[C:29](=[CH:30][CH:31]=[CH:32][CH:33]=2)[CH:28]=[CH:27][N:26]=1>>[NH2:45][CH2:44][C@@H:38]1[C@H:39]([CH3:43])[CH2:40][CH2:41][CH2:42][N:37]1[C:35]([C:25]1[C:34]2[C:29](=[CH:30][CH:31]=[CH:32][CH:33]=2)[CH:28]=[CH:27][N:26]=1)=[O:36]参加物
3
実験手順
The title compound was synthesized following the same general protocol as described for ((2S,3R)-2-(aminomethyl)-3-methylpiperidin-1-yl)(5-methyl-2-(1-methyl-1H-pyrazol-4-yl)phenyl)methanone in Example A1, using 2-(((2S,3R)-1-(isoquinoline-1-carbonyl)-3-methylpiperidin-2-yl)methyl)isoindoline-1,3-dione. ESI-MS (m/z): 284 [M+1]+.
出典と根拠
- ORDレコード
- ord-d0c4af0bc03b41128cb4bfb3fb9808a7
- 出典データセット
- uspto-grants-2016_09
- 特許番号
- US09440982B2
関連ノート
読み込み中…